Effects of Biased Opioid Agonists on Gastrointestinal Recovery After Gynecologic Laparoscopic Surgery
Effects of Biased Opioid Receptor Agonists on Postoperative Gastrointestinal Function Recovery in Patients Undergoing Gynecologic Laparoscopic Surgery
This randomized controlled clinical trial aims to evaluate the effects of different opioid analgesics on gastrointestinal recovery after gynecologic laparoscopic surgery.
Opioid medications are commonly used to manage pain after surgery, but they may cause nausea, vomiting, constipation, and delayed recovery of bowel function. Biased μ-opioid receptor agonists, such as tegileridine and oliceridine, may provide effective pain relief with fewer gastrointestinal side effects than conventional opioids.
The main question is whether biased opioid receptor agonists can shorten the time to postoperative gastrointestinal recovery compared with sufentanil, a conventional opioid analgesic.
The study plans to enroll 212 adults undergoing elective gynecologic laparoscopic surgery. Participants will be randomly assigned to one of four groups:
- Lower-dose tegileridine
- Higher-dose tegileridine
- Oliceridine
- Sufentanil
After surgery, participants will receive the assigned medication through a patient-controlled intravenous analgesia (PCIA) pump.
The primary outcome is time to gastrointestinal recovery (GI-2), defined as the time from the end of surgery until both the first bowel movement (defecation) and tolerance of solid food have occurred. The later of these two events determines the GI-2 recovery time.
Researchers will also assess the time to first passage of flatus, postoperative nausea and vomiting, gastrointestinal function scores, pain intensity, gastrointestinal ultrasound findings, analgesic requirements, and medication-related adverse events.
The findings may help determine whether biased opioid receptor agonists offer advantages over conventional opioid analgesics in supporting gastrointestinal recovery while maintaining adequate postoperative pain control.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Postoperative gastrointestinal dysfunction is a common concern following gynecologic laparoscopic surgery. Although opioid analgesics are widely used for postoperative pain management, their effects on gastrointestinal motility may contribute to delayed bowel function recovery, postoperative nausea and vomiting, and patient discomfort.
Biased μ-opioid receptor agonists have been developed to provide analgesia through preferential activation of specific opioid receptor signaling pathways. Tegileridine and oliceridine are of clinical interest because of their potential to provide effective postoperative analgesia while reducing certain opioid-associated adverse effects. However, their effects on gastrointestinal recovery following gynecologic laparoscopic surgery remain to be established.
This study is a prospective, randomized, controlled, single-center clinical trial conducted at the Second Affiliated Hospital of Hainan Medical University. A total of 212 adult patients undergoing elective gynecologic laparoscopic surgery are planned to be enrolled.
Participants will be randomly allocated to four parallel treatment groups receiving postoperative patient-controlled intravenous analgesia (PCIA) with one of the following regimens:
- Tegileridine 0.07 mg/kg
- Tegileridine 0.11 mg/kg
- Oliceridine 0.36 mg/kg
- Sufentanil 2.0 micrograms/kg
The primary outcome is time to gastrointestinal recovery (GI-2), defined as the time from the end of surgery until both the first bowel movement (defecation) and tolerance of solid food have occurred. GI-2 recovery time is determined by the later of these two events and is measured in hours.
Secondary outcomes include time to first passage of flatus, time to first bowel movement, postoperative gastrointestinal function assessed using the I-FEED score, postoperative nausea and vomiting, postoperative pain intensity assessed using the Visual Analog Scale (VAS), patient-controlled analgesia use, rescue analgesia requirements, and medication-related adverse events.
Gastrointestinal ultrasound examinations will be performed to assess postoperative gastrointestinal function, including gastric antral cross-sectional area and small bowel peristaltic activity. These measurements are intended to provide additional objective information about gastrointestinal recovery.
The study will compare postoperative gastrointestinal recovery, analgesic effectiveness, and safety outcomes across the four treatment groups. The findings may provide clinical evidence to inform the selection of postoperative opioid analgesic regimens for patients undergoing gynecologic laparoscopic surgery.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 4
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Shuangqing Wu
- Número de teléfono: 8618390551805
- Correo electrónico: 1067382988@qq.com
Ubicaciones de estudio
-
-
Hainan
-
Haikou, Hainan, Porcelana, 571199
- Reclutamiento
- The Second Affiliated Hospital of Hainan Medical University
-
Contacto:
- Shuangqing Wu
- Número de teléfono: 8618390551805
- Correo electrónico: 1067382988@qq.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Female patients aged 18 to 75 years scheduled for elective gynecologic laparoscopic surgery.
- American Society of Anesthesiologists (ASA) physical status I-III.
- Body mass index (BMI) between 18 and 30 kg/m².
- Normal preoperative liver and kidney function, with cardiopulmonary function adequate to tolerate surgery.
- Voluntary provision of written informed consent.
Exclusion Criteria:
- Inability to provide informed consent before surgery or difficulty communicating.
- Known allergy to any of the study medications.
- Severe hepatic impairment (Child-Pugh class C), severe renal impairment (creatinine clearance below 30 mL/min), or ongoing long-term dialysis.
- Severe cardiovascular or cerebrovascular disease, including myocardial infarction, cardiac arrest, decompensated heart failure, significant arrhythmias (such as second-degree or higher atrioventricular block without a pacemaker), congenital heart disease, severe valvular disease, extensive cerebral hemorrhage, or cerebral infarction; or significant respiratory disease, including a history of asthma, acute exacerbation of chronic obstructive pulmonary disease, or previous pulmonary resection.
- History of long-term opioid use before surgery or chronic pain.
- Pregnancy or breastfeeding.
- Other severe medical conditions or psychiatric disorders that make participation in the study unsuitable.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Low-Dose Tegileridine
Participants receive postoperative patient-controlled intravenous analgesia (PCIA) with tegileridine at a prescribed dose of 0.07 mg/kg. |
Tegileridine is administered by patient-controlled intravenous analgesia (PCIA) after gynecologic laparoscopic surgery. The prescribed dose is 0.07 mg/kg in the low-dose group and 0.11 mg/kg in the high-dose group. Participants receive only their assigned dose regimen. |
|
Experimental: High-Dose Tegileridine
Participants receive postoperative patient-controlled intravenous analgesia (PCIA) with tegileridine at a prescribed dose of 0.11 mg/kg. |
Tegileridine is administered by patient-controlled intravenous analgesia (PCIA) after gynecologic laparoscopic surgery. The prescribed dose is 0.07 mg/kg in the low-dose group and 0.11 mg/kg in the high-dose group. Participants receive only their assigned dose regimen. |
|
Experimental: Oliceridine
Participants receive postoperative patient-controlled intravenous analgesia (PCIA) with oliceridine at a prescribed dose of 0.36 mg/kg. |
Oliceridine is administered by patient-controlled intravenous analgesia (PCIA) after gynecologic laparoscopic surgery at a prescribed dose of 0.36 mg/kg. |
|
Experimental: Sufentanil
Participants receive postoperative patient-controlled intravenous analgesia (PCIA) with sufentanil at a prescribed dose of 2.0 micrograms/kg. |
Sufentanil is administered by patient-controlled intravenous analgesia (PCIA) after gynecologic laparoscopic surgery at a prescribed dose of 2.0 micrograms/kg. This group serves as the active comparator. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to Gastrointestinal Recovery (GI-2)
Periodo de tiempo: From the end of surgery up to 7 days postoperatively.
|
GI-2 is defined as the time from the end of surgery until both the first bowel movement (defecation) and tolerance of solid food have occurred. The later of these two events determines the GI-2 recovery time, measured in hours. Participants who do not achieve GI-2 within 7 days will be recorded as not having reached the endpoint during the follow-up period. |
From the end of surgery up to 7 days postoperatively.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to First Passage of Flatus
Periodo de tiempo: From the end of surgery up to 7 days postoperatively.
|
Time from the end of surgery to the first passage of flatus, measured in hours. A shorter time indicates earlier recovery of postoperative bowel function. |
From the end of surgery up to 7 days postoperatively.
|
|
Postoperative Gastrointestinal Function (I-FEED Score)
Periodo de tiempo: At 6, 24, and 48 hours postoperatively.
|
Gastrointestinal function assessed using the I-FEED score at each scheduled postoperative assessment. The protocol describes a score ranging from 0 to 10, with higher scores indicating worse gastrointestinal function. |
At 6, 24, and 48 hours postoperatively.
|
|
Postoperative Pain Intensity (VAS Score)
Periodo de tiempo: At 6, 24, and 48 hours postoperatively.
|
Postoperative pain intensity assessed using a 0-to-10 Visual Analog Scale, where 0 indicates no pain and 10 indicates the worst imaginable pain. Scores are recorded at each scheduled assessment. |
At 6, 24, and 48 hours postoperatively.
|
|
Incidence of Postoperative Nausea and Vomiting
Periodo de tiempo: Within 48 hours postoperatively.
|
Percentage of participants experiencing at least one episode of nausea or vomiting within 48 hours after surgery. |
Within 48 hours postoperatively.
|
|
Small Bowel Peristaltic Frequency
Periodo de tiempo: At 6, 24, and 48 hours postoperatively.
|
Frequency of small bowel peristaltic movements assessed by ultrasonography, expressed as contractions per minute. |
At 6, 24, and 48 hours postoperatively.
|
|
Incidence of Opioid-Related Adverse Reactions
Periodo de tiempo: Within 48 hours postoperatively.
|
Percentage of participants experiencing at least one opioid-related adverse reaction, including dizziness, somnolence, respiratory depression, pruritus, abdominal distension, or constipation, within 48 hours after surgery. |
Within 48 hours postoperatively.
|
|
Number of Patient-Controlled Analgesia Button Presses
Periodo de tiempo: Within 48 hours postoperatively.
|
Total number of patient-initiated button presses recorded by the patient-controlled intravenous analgesia pump during the first 48 hours after surgery. |
Within 48 hours postoperatively.
|
|
Number of Rescue Analgesia Administrations
Periodo de tiempo: Within 48 hours postoperatively.
|
Total number of rescue analgesic administrations received by each participant within 48 hours after surgery. |
Within 48 hours postoperatively.
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2026-K51-01
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .